Just won an award.....very Isable..(if you can put it that way)..another of Robbie Burns clever stock picks....decided myself to join in...not sure how high this could go but looking good at the moment !.

OPT OPTOS

Just out....

16 Nov Optos PLC OPTS Panmure Gordon Buy 185.75 184.75 320.00 320.00 Retains

SP TARGET a whopping 320p.

OPT OPTOS

just out another reco

16 Nov Optos PLC OPTS Jefferies International Buy 185.50 184.75 280.00 280.00 Retains

280p SP Tatget.

Historical item on OPTS

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=20441825

OPT OPTOS

Remember results wed.

Article linked to them below.


Strong end to the year for Optos
Mon 15 Oct 2012

OPTS - Optos

Latest Prices
Name Price %
Optos 179.50p -2.84%

FTSE All-Share 2,940 -0.98%
FTSE Small Cap 3,186 -0.79%
techMARK 2,024 -0.87%
techMARK 100 2,351 -0.65%
Health Care Equipment & Services 3,634 -0.77%

LONDON (SHARECAST) - Optos saw shares rise strongly on Monday morning after saying that both turnover and operating profit for the year ending September 30th was ahead of market expectations.

The ophthalmology equipment maker reported that, following strong sales in the last quarter, “revenues are expected to exceed $190m”, ahead of consenus expectations of $183m, with operating profit expected to be “slightly above market consensus” of $22.3m.

Manufacture of its latest product range, the Daytona, has reached current planned capacity in the last quarter, allowing the full year (ending 2012) order backlog to be fully cleared and resulting in an installed base of 329 devices at the end of September 2012.

As stated in its third-quarter interim management statement, the company expects “gross margins to improve during full year 2013 as Daytona volumes increase”.

Chief Executive Officer Roy Davis commented: “I am delighted with the company’s achievements this year and in particular, the manufacturing scale-up and market roll-out of Daytona.

"The reaction to this instrument has been very positive and I am excited by the opportunities it brings to the business. Our near-term focus is to drive sales of Daytona in all our key markets and to continue our success with the 200Tx instrument in the ophthalmology market.”


Broker reaction


Broker reaction to the update has been equally positive. Numis has reiterated its “buy” rating and 300p share price target, while Jefferies, which also has a “buy” rating, has raised its price target to 280p from 270p.

Meanwhile, Panmure Gordon has upgraded its rating from 'hold' to 'buy', saying that Optos "should be a core holding to investors looking to have healthcare in their portfolio". The broker raised its target price for the shares from 230p to 320p.

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=20427759

Lets hope this turns direction with some good news

Last trading statement....

results wed tomorrow........

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=20427759

Losing ground ?

Yeap across road at iii guy reckons its MMs storing stock for good results tomorrow.?.

Been a few recent days where demand stronger than supply but SP dropped. he maybe right he maybe wrong.

We'l know in the morning, fingers crossed.

Thanks for that update g.

Looks like it moves fast on good news looking back to March/April .

OPTOS PLC

Preliminary Results FY12

Highlights



Strong financial performance ahead of expectations

- Revenue and other operating income(1) up 37% to $196.4m

- 15% underlying revenue growth(2)

- $21.0m revenue from Daytona, our next generation desktop retinal imaging device, with 329 devices installed this year

- Timing of manufacturing scale up of Daytona contributed to a fall in gross margin from 64% to 57%(3)

- In a year of significant investment, profit before tax and exceptional items increased 16% to $26.3m versus $22.7m last year

- Diluted EPS post-exceptional was 25% lower at 23.9 cents from 31.8 cents reflecting acquisition-related charges, and for the first time, a net tax charge on profits

- Investment in the business, and the increase in self-funded finance leases, contributed to a cash decrease of $3.6m in the year

- A three year bank facility of $30m was taken on to finance the OPKO acquisition, contributing to a net debt increase to $47.9m



Increased geographical reach

- Our two geographic segments both grew in double digits

- North American sales grew 26% to $147.8m

- International sales grew 85% to $48.6m

- Strengthened positions in Europe, Middle East and Asia



Investment in the product range

- Completion of manufacturing scale-up and market roll-out of Daytona

- Continued progress on the development project to combine our ultra wide-field retinal imaging technology with ocular coherence tomography ("OCT") into a single device



Accelerated growth in ophthalmology

- Over 320 200Tx devices installed globally, including into key ophthalmology centres in the USA, Germany, Jeddah, Dubai, Abu Dhabi, as well as Japan





http://www.moneyam.com/action/news/showArticle?id=4488583

Looks good

Excelent results ahead of expectations.

The company were up against concensous
figures of........

OPTS

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Sep-12 117.32 14.56 13.71p 12.7 n/a -33% n/a 0.0%

Digital Look

Pre Tax 14.56

in fact theyhave done converted to british pounds.....

ncy CalculatorAmount: US $


Converted: £
Calculator History
US $26.3 = £16.55


16.55

Threfore 14.56 V 16.55 actualy gained = outperformed
Concensous broker figures.

Summary and Outlook



During the last financial year we have delivered a significant increase in revenues and grown profits whilst making important investments for the long term growth of the business. We are absolutely delighted with the response to Daytona which we believe will be central to the international expansion of the business and will enable Optos to achieve a further major transition. Our growing body of clinical evidence demonstrates the critical importance of retinal diagnostics in the periphery. Looking forward to the next financial year, our priority will be to execute on Daytona and continue our expansion into the ophthalmology market with the 200Tx device.



Roy Davis

Chief Executive Officer

FROM iii.....

That have delivered profits which are $4 Million over the market consensus and with good growth evident in the American market.

Should hopefully drive a fairly decent rerating upwards.

Imvho and please dyor.

We need a 25% rise :-))

21 Nov Optos PLC OPTS Investec Hold 0.00 165.00 202.00 - Under Review

202p SP target under review.

Upgrade me thinks on the way.

Just a shame it fell so far pre the results